Supplemental Table 1: Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Guidelines for Cohort Studies.

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the	1
		abstract	2
		(b) Provide in the abstract an informative and balanced summary of what	2
		was done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3-4
Objectives	3	State specific objectives, including any prespecified hypotheses	4-5
Methods			•
Study design	4	Present key elements of study design early in the paper	6-7
Setting	5	Describe the setting, locations, and relevant dates, including periods of	6
Seame		recruitment, exposure, follow-up, and data collection	
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of	5-6
Tartelpants		participants. Describe methods of follow-up	
		(b) For matched studies, give matching criteria and number of exposed and	NA
		unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders,	8
v arrables	,	and effect modifiers. Give diagnostic criteria, if applicable	
Data sources/	8*	For each variable of interest, give sources of data and details of methods of	8-9
measurement	0	assessment (measurement). Describe comparability of assessment methods	
measurement		if there is more than one group	
Bias	9		NA
		Describe any efforts to address potential sources of bias	NA
Study size	10	Explain how the study size was arrived at	9
Quantitative	11	Explain how quantitative variables were handled in the analyses. If	
variables	12	applicable, describe which groupings were chosen and why	9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	
		(b) Describe any methods used to examine subgroups and interactions	NA
		(c) Explain how missing data were addressed	NA
		(d) If applicable, explain how loss to follow-up was addressed	NA
		(e) Describe any sensitivity analyses	NA
Results			
	13*	(a) Report numbers of individuals at each stage of study—eg numbers	10
Participants	13.	potentially eligible, examined for eligibility, confirmed eligible, included in	Table 1
		the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	10-11
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical,	Table 1
		social) and information on exposures and potential confounders	
		(b) Indicate number of participants with missing data for each variable of interest	11
		(c) Summarise follow-up time (eg, average and total amount)	11-12
Outcome data	15*	Report numbers of outcome events or summary measures over time	11-12
Sateonie data		Topost hamoers of outcome events of summary measures over time	Table 2

Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted	NA
		estimates and their precision (eg, 95% confidence interval). Make clear	
		which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	NA
		(c) If relevant, consider translating estimates of relative risk into absolute	NA
		risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
Discussion			
Key results	18	Summarise key results with reference to study objectives	12-13
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias	14-15
		or imprecision. Discuss both direction and magnitude of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives,	14-15
		limitations, multiplicity of analyses, results from similar studies, and other	
		relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	15-16
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study	17
		and, if applicable, for the original study on which the present article is based	